BACKGROUND: To determine the maximally tolerated dose (MTD) of capecitabine when given concomitantly with carboplatin and intensity-modulated radiation therapy (IMRT) for treatment of localized stage III/IV squamous cell carcinomas of the head and neck (HNSCC). PATIENTS AND METHODS: After six weeks of induction chemotherapy with capecitabine and carboplatin, patients received a second course with concomitant IMRT. The MTD for capecitabine during chemoradiation was determined by a standard phase I trial design. RESULTS: Nine out of the eleven patients qualified for chemoradiation. With weekly carboplatin AUC=1.5 and IMRT, the MTD of capecitabine was 850 mg/m(2)/day when given in divided doses on days 1-14 and 22-35. The dose-limiting toxicity was myleosuppression and other adverse effects were modest. Eight patients experienced complete response after chemoradiation and seven remain relapse-free after 34 months. CONCLUSION: Capecitabine, carboplatin, and IMRT given as described were well tolerated by HNSCC patients and in this pilot study produced a promising rate of disease control.
BACKGROUND: To determine the maximally tolerated dose (MTD) of capecitabine when given concomitantly with carboplatin and intensity-modulated radiation therapy (IMRT) for treatment of localized stage III/IV squamous cell carcinomas of the head and neck (HNSCC). PATIENTS AND METHODS: After six weeks of induction chemotherapy with capecitabine and carboplatin, patients received a second course with concomitant IMRT. The MTD for capecitabine during chemoradiation was determined by a standard phase I trial design. RESULTS: Nine out of the eleven patients qualified for chemoradiation. With weekly carboplatin AUC=1.5 and IMRT, the MTD of capecitabine was 850 mg/m(2)/day when given in divided doses on days 1-14 and 22-35. The dose-limiting toxicity was myleosuppression and other adverse effects were modest. Eight patients experienced complete response after chemoradiation and seven remain relapse-free after 34 months. CONCLUSION:Capecitabine, carboplatin, and IMRT given as described were well tolerated by HNSCC patients and in this pilot study produced a promising rate of disease control.
Authors: J Martinez-Trufero; D Isla; J C Adansa; A Irigoyen; R Hitt; I Gil-Arnaiz; J Lambea; M J Lecumberri; J J Cruz Journal: Br J Cancer Date: 2010-05-18 Impact factor: 7.640